# ZUNVEYL (benzgalantamine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/benzgalantamine

> The FDA approved ZUNVEYL (benzgalantamine), sponsored by Alpha Cognition Inc. (ACOG), on July 29, 2024 for mild-to-moderate Alzheimer's disease.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is ZUNVEYL (benzgalantamine) FDA approved?

Yes. The FDA approved ZUNVEYL (benzgalantamine), sponsored by Alpha Cognition Inc. (ACOG), on July 29, 2024 for mild-to-moderate Alzheimer's disease. SEC Form 10-Q: "On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration ("FDA") for the commercialization of ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease." [Calendar and source filings](https://sec-api.dev/pdufa/benzgalantamine)

Source: SEC Form 10-Q, accession 0001213900-25-110061, https://www.sec.gov/Archives/edgar/data/1655923/000121390025110061/ea0263490-10q_alpha.htm (retrieved 2026-11-12). Last confirmed 2025-11-13. Cite: https://sec-api.dev/pdufa/benzgalantamine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ZUNVEYL (benzgalantamine) |
| Codes | ALPHA-1062 |
| Sponsor | Alpha Cognition Inc. (ACOG) https://sec-api.dev/companies/acog/catalysts |
| Indications | [mild-to-moderate alzheimer's disease](https://sec-api.dev/indications/mild-to-moderate-alzheimer-s-disease), mild to moderate dementia of the alzheimer's type in adults |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 7, 2023: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2024-12-31, last confirmed 2024-12-31.
- SEC registration statement (S-1) (accession 0001213900-24-114064): "On December 7, 2023, the Company announced that the FDA accepted the Company's new drug application NDA for ZUNVEYL formerly ALPHA-1062 and has granted a PDUFA goal date of July 27, 2024." https://www.sec.gov/Archives/edgar/data/1655923/000121390024114064/ea0217603-04.htm

### July 27, 2024: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2024-12-31, last confirmed 2024-12-31.
- SEC registration statement (S-1) (accession 0001213900-24-114064): "On December 7, 2023, the Company announced that the FDA accepted the Company's new drug application NDA for ZUNVEYL formerly ALPHA-1062 and has granted a PDUFA goal date of July 27, 2024." https://www.sec.gov/Archives/edgar/data/1655923/000121390024114064/ea0217603-04.htm
- SEC Form 10-Q (accession 0001213900-25-110061): "On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration ("FDA") for the commercialization of ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1655923/000121390025110061/ea0263490-10q_alpha.htm

### July 29, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: mild-to-moderate Alzheimer's disease.
- First seen 2024-11-14, last confirmed 2025-11-13.
- SEC Form 10-Q (accession 0001213900-25-110061): "On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration ("FDA") for the commercialization of ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1655923/000121390025110061/ea0263490-10q_alpha.htm
- SEC Form 10-Q (accession 0001213900-25-076600): "On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration ("FDA") for the commercialization of ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1655923/000121390025076600/ea0250497-10q_alpha.htm
- SEC Form 10-Q (accession 0001213900-25-044163): "On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration ("FDA") for the commercialization of ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1655923/000121390025044163/ea0239900-10q_alpha.htm
- SEC Form 10-K (accession 0001213900-25-026225): "The NDA for ZUNVEYL oral tablets was approved by the FDA on July 26, 2024, but all our other product candidates are in the pre-clinical stage." https://www.sec.gov/Archives/edgar/data/1655923/000121390025026225/ea0233390-10k_alpha.htm
- SEC Form 10-K (accession 0001213900-25-026225): "On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration (FDA) for the commercialization of ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1655923/000121390025026225/ea0233390-10k_alpha.htm
- SEC registration statement (S-1) (accession 0001213900-24-114064): "On July 26, 2024, the Company received approval by the FDA of its NDA for ZUNVEYL delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults (Alzheimer's disease)." https://www.sec.gov/Archives/edgar/data/1655923/000121390024114064/ea0217603-04.htm
- SEC registration statement (S-1) (accession 0001213900-24-114064): "On July 26, 2024, the Company received approval by the FDA of the Company's NDA for ZUNVEYL delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults." https://www.sec.gov/Archives/edgar/data/1655923/000121390024114064/ea0217603-04.htm
- SEC registration statement (S-1) (accession 0001213900-24-114064): "The NDA for ZUNVEYL oral tablets was approved by the FDA on July 26, 2024, but all our other product candidates are in the pre-clinical stage." https://www.sec.gov/Archives/edgar/data/1655923/000121390024114064/ea0217603-04.htm
- SEC registration statement (S-1) (accession 0001213900-24-114064): "On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration (FDA) for the commercialization of ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1655923/000121390024114064/ea0217603-04.htm
- SEC Form 10-Q (accession 0001213900-24-098409): "On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration (FDA) for the commercialization of ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1655923/000121390024098409/ea0220014-10q_alpha.htm
- SEC Form 10-Q (accession 0001213900-24-098409): "On July 26, 2024, the Company received approval by the FDA of the Company's New Drug Application (the "NDA") for ZUNVEYL® (benzgalantamine)" https://www.sec.gov/Archives/edgar/data/1655923/000121390024098409/ea0220014-10q_alpha.htm
- SEC registration statement (S-1) (accession 0001213900-24-114064): "On July 26, 2024, the Company received approval by the FDA of the Company's New Drug Application (the "NDA") for ZUNVEYL™ (benzgalantamine) previously known as ALPHA-1062 ("ZUNVEYL" or "ALPHA-1062") a delayed release oral tablet formulation indicated for the treatment mild to moderate dementia of the Alzheimer's type in adults (Alzheimer's disease)." https://www.sec.gov/Archives/edgar/data/1655923/000121390024114064/ea0217603-04.htm

## Same indication

- [Simufilam](https://sec-api.dev/pdufa/simufilam) (FLNA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/benzgalantamine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ZUNVEYL (benzgalantamine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/benzgalantamine

```bibtex
@misc{secapidev_pdufa_benzgalantamine_20261116,
  title        = {ZUNVEYL (benzgalantamine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/benzgalantamine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_benzgalantamine_20261116","title":"ZUNVEYL (benzgalantamine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/benzgalantamine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
